Brief: Galapagos Presented New Atalanta-1 Cell Therapy Data In MCL
08/12/2025 06:34
Dec 8 (Reuters) - Galapagos NV GLPG.AS: REG-GALAPAGOS PRESENTED NEW ATALANTA-1 CELL THERAPY DATA IN MCL AT ASH 2025 AMONG INFUSED PATIENTS OBJECTIVE RESPONSE RATE (ORR) WAS 100%, WITH COMPLETE RESPONSE RATE (CRR) OF 96% GLPG5101 SHOWS ENCOURAGING SAFETY PROFILE IN MCL STUDY GALAPAGOS REMAINS FOCUSED ON THE INTENTION TO WIND DOWN THE CELL THERAPY ACTIVITIES GLPG5101 DEMONSTRATED ROBUST IN VIVO CAR T-CELL EXPANSION AND LONG-TERM PERSISTENCE Source text: ID:nGNE4SXT97 Further company coverage: GLPG.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors